HC Wainwright Analysts Boost Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Research analysts at HC Wainwright upped their Q4 2024 earnings per share estimates for Harrow in a research note issued on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.16 per share for the quarter, up from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Trading Up 1.1 %

NASDAQ HROW opened at $28.41 on Friday. Harrow has a 12 month low of $9.86 and a 12 month high of $59.23. The stock has a market cap of $1.01 billion, a P/E ratio of -30.22 and a beta of 0.69. The stock’s fifty day moving average price is $29.51 and its 200-day moving average price is $38.40. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Institutional Investors Weigh In On Harrow

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Harrow during the fourth quarter valued at $25,000. Quest Partners LLC purchased a new position in Harrow during the 3rd quarter valued at approximately $29,000. Tower Research Capital LLC TRC grew its holdings in Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after buying an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Harrow in the 4th quarter worth approximately $78,000. Finally, AlphaQuest LLC boosted its holdings in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.